ASPIRIN PRIMARY PREVENTION DATA SHOW SMALL BUT SIGNIFICANT EFFECT: FURTHER TRIALS
This article was originally published in The Tan Sheet
Executive Summary
ASPIRIN PRIMARY PREVENTION DATA SHOW SMALL BUT SIGNIFICANT EFFECT: FURTHER TRIALS, however, are needed before daily aspirin use by healthy individuals can be recommended for prevention of primary vascular events, Richard Peto, Oxford University, et al., suggested in a large-scale, meta-analysis of data from 257 aspirin studies published in the Jan. 7 issue of the British Medical Journal. The study evaluates antiplatelet therapy, primarily aspirin, for three distinct groups: primary prevention; treatment for acute myocardial infarction and unstable angina; and for secondary prevention of myocardial infarction, angina, stroke, transient ischemic attack, arterial bypass surgery or angioplasty.